Sticky platelet syndrome and thrombocythemia (Q34182628)

31 July 2017

1 reference

title

Sticky platelet syndrome and thrombocythemia (English)

1 reference

31 July 2017

main subject

sticky platelet syndrome

1 reference

Eugene P Frenkel

1

1 reference

31 July 2017

Eberhard F Mammen

series ordinal

2

1 reference

31 July 2017

publication date

1 February 2003

1 reference

Hematology / Oncology Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

17

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

63-83

1 reference

Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Hereditary and acquired thrombophilia. Part I. Preface

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Insulin enhances platelet activation in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet function tests in thrombotic cerebrovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Evidence of enhanced platelet aggregation and platelet sensitivity in migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Adrenaline-induced hyperaggregability of platelets and enhanced thromboxane release in anorexia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet function in bilateral acute retinal necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Plasma platelet aggregating factor and platelet aggregation studies in pre-eclampsia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Intravascular Platelet Aggregation in the Heart Induced by Stress

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Adrenaline and experimental thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Circadian variation in platelet function in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet lipoxygenase defect (Wien-Penzing defect) in two patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Sticky platelet syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet hyperaggregability in patients with chest pain and angiographically normal coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Sticky Platelet Syndrome: A Cause of Neurovascular Thrombosis and Thrombo-Embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

The clinical spectrum of thrombocytosis and thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Proposal for Revised Diagnostic Criteria of Essential Thrombocythemia and Polycythemia Vera by the Thrombocythemia Vera Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Thrombotic complications in essential thrombocythemia with relatively low platelet counts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Functional and morphological studies of platelet reactivity with vessel wall subendothelium in chronic myeloproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet and Plasma β Thromboglobulin in Mycloproliferative Syndromes and Secondary Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Platelet Hyperaggregability and Thrombosis in Patients with Thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

The management of 'low-risk' and 'intermediate-risk' patients with primary thrombocythaemia. MPD (UK) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Erythromelalgia: A Pathognomonic Microvascular Thrombotic Complication in Essential Thrombocythemia and Polycythemia Vera

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Histopathology of erythromelalgia in thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Aspirin in Essential Thrombocythemia: Status Quo and Quo Vadis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Essential Thrombocythaemia and Peripheral Gangrene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Neurologic and Visual Symptoms in Essential Thrombocythemia: Efficacy of Low-Dose Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Acquired von Willebrand disease in patients with high platelet counts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Relation of Platelet Abnormalities to Thrombosis and Hemorrhage in Chronic Myeloproliferative Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Management of essential thrombocythaemia during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Essential thrombocythemia associated with recurrent abortions and fetal growth retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Primary thrombocythemia in pregnancy: A report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Essential Thrombocythemia in Childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

No treatment for low-risk thrombocythaemia: results from a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Essential thrombocythemias. Clinical evolutionary and biological data

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Clinical manifestations of essential thrombocythemia in young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Clinical course of essential thrombocythemia in 147 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Essential thrombocythemia. Clinical characteristics and course of 61 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Interferon-alpha therapy in polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Alpha-interferon therapy for essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Long-term interferon therapy for thrombocytosis in myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Anagrelide: A New Drug for Treating Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

The effects of anagrelide on human megakaryocytopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900096-5

7 January 2021

10.1016/S0889-8588(02)00096-5

Identifiers

DOI

1 reference

31 July 2017

1 reference